Voisin Consulting Life Sciences publication icon

Considerations for Developing EU Risk Management Plans

Post thumbnail Considerations for Developing EU Risk Management Plans

This article aims to share some key considerations when defining the strategy for the preparation of a risk management plan (RMP). The RMP is required to be submitted when applying for an EU marketing authorisation application (MAA). Advice is offered to applicants and medicinal product developers to maximise the utility of the RMP, in both the marketing authorisation approval process and in the post-marketing setting.

The following two scenarios are described: when RMP preparation is initiated early during the product development (mostly applicable to new chemical/new biological entities, NCEs/NBEs), and when the RMP is prepared later, ie, at the time of MAA (mostly applicable to generics or hybrid applications).


Published on: February, 2021
Voisin Consulting Life Sciences download icon

Download the full publication now

Fill in the form to download the content

    Yes, I would like to receive communications regarding VCLS services and events

    publication by

    Alina Tudor thumbnail
    Alina Tudor
    Director Vigilance Operations
    Julie Taccoen thumbnail
    Julie Taccoen
    Senior Regulatory Scientist Drugs & Biologics

    More resources